文献速递乳腺癌

帕博利珠单抗联合曲妥珠单抗治疗曲妥珠单抗耐药的晚期HER2阳性乳腺癌(PANACEA):单臂、多中心、1b-2期试验

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
PubMed 文献 · Lancet Oncol · 2019-02-11

PANACEA研究在11个中心纳入58例曲妥珠单抗耐药的晚期HER2阳性乳腺癌患者,评估帕博利珠单抗联合曲妥珠单抗的安全性和抗肿瘤活性。1b期未观察到剂量限制性毒性;2期PD-L1阳性患者客观缓解率为15%(6/40,90% CI 7-29),PD-L1阴性患者无客观缓解。联合方案安全性可管理,在PD-L1阳性患者中显示活性和持久临床获益。

要点

  • 1b期未观察到剂量限制性毒性,帕博利珠单抗联合曲妥珠单抗方案安全。
  • PD-L1阳性患者客观缓解率为15%(6/40,90% CI 7-29),PD-L1阴性患者无客观缓解。
  • 3-5级不良事件发生率50%(29/58),治疗相关3-5级不良事件29%(17/58),发生1例治疗相关死亡(Lambert-Eaton综合征)。

核心结论

  • 帕博利珠单抗联合曲妥珠单抗在PD-L1阳性、曲妥珠单抗耐药的晚期HER2阳性乳腺癌患者中安全,并显示出活性和持久临床获益。
  • 作者认为该乳腺癌亚型的进一步研究应聚焦PD-L1阳性人群,并应在较少经治的患者中进行。

研究设计与样本

  • 单臂、多中心、1b-2期试验,在5个国家的11个中心开展。
  • 纳入18岁及以上女性,晚期组织学确诊HER2阳性乳腺癌,既往曲妥珠单抗治疗期间记录到进展,ECOG体能状态0或1,并提供FFPE转移瘤活检用于中心评估PD-L1状态。
  • 1b期纳入PD-L1阳性肿瘤患者,采用3+3剂量递增,静脉帕博利珠单抗2 mg/kg和10 mg/kg每3周联合静脉曲妥珠单抗6 mg/kg。
  • 2015年8月28日方案修订规定所有默克资助试验中帕博利珠单抗统一为200 mg每3周固定剂量;2期PD-L1阳性和PD-L1阴性患者平行入组,接受固定剂量帕博利珠单抗联合标准曲妥珠单抗。
  • 1b期主要终点为剂量限制性毒性发生率和2期推荐剂量;2期主要终点为PD-L1阳性患者达到客观缓解的比例。

主要发现

  • 2015年2月2日至2017年4月5日,1b期入组6例(帕博利珠单抗2 mg/kg组3例,10 mg/kg组3例),2期入组52例(PD-L1阳性40例,PD-L1阴性12例);数据分析截止2017年8月7日。
  • 1b期测试的剂量队列中未观察到剂量限制性毒性。
  • 2期PD-L1阳性患者中位随访13.6个月(IQR 11.6-18.4),PD-L1阴性患者中位随访12.2个月(IQR 7.9-12.2)。
  • 40例PD-L1阳性患者中6例达到客观缓解(15%,90% CI 7-29);PD-L1阴性患者中无客观缓解者。
  • 最常见的任何级别治疗相关不良事件为疲乏(12/58,21%);3-5级不良事件发生29例(50%),治疗相关3-5级不良事件17例(29%),严重不良事件29例(50%)。

关键数值与推荐

  • 2期主要终点:PD-L1阳性患者客观缓解率为15%(6/40,90% CI 7-29)。
  • PD-L1阴性患者客观缓解率为0(0/12)。
  • 1b期剂量限制性毒性发生率为0(2 mg/kg组3例和10 mg/kg组3例中均未观察到)。
  • 3-5级不良事件发生率50%(29/58),治疗相关3-5级不良事件发生率29%(17/58),严重不良事件发生率50%(29/58)。

临床怎么用

  • 原文未据此给出临床推荐。
  • 作者认为进一步研究应聚焦PD-L1阳性人群,并应在较少经治的患者中进行。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, added to trastuzumab in trastuzumab-resistant, advanced HER2-positive breast cancer. METHODS: We did this single-arm, multicentre, phase 1b-2 trial in 11 centres based in five countries. Eligible participants were women aged 18 years or older, who had advanced, histologically confirmed, HER2-positive breast cancer; documented progression during previous trastuzumab-based therapy; an Eastern Cooperative Oncology Group performance status of 0 or 1; and a formalin-fixed, paraffin-embedded metastatic tumour biopsy for central assessment of programmed cell death 1 ligand 1 (PD-L1) status. In phase 1b, we enrolled patients with PD-L1-positive tumours in a 3 + 3 dose-escalation of intravenous pembrolizumab (2 mg/kg and 10 mg/kg, every 3 weeks) plus 6 mg/kg of intravenous trastuzumab. The primary endpoint of the phase 1b study was the incidence of dose-limiting toxicity and recommended phase 2 dose; however, a protocol amendment on Aug 28, 2015, stipulated a flat dose of pembrolizumab of 200 mg every 3 weeks in all Merck-sponsored trials. In phase 2, patients with PD-L1-positive and PD-L1-negative tumours were enrolled in parallel cohorts and received the flat dose of pembrolizumab plus standard trastuzumab. The primary endpoint of the phase 2 study was the proportion of PD-L1-positive patients achieving an objective response. This trial is registered in ClinicalTrials.gov, number NCT02129556, and with EudraCT, number 2013-004770-10, and is closed. FINDINGS: Between Feb 2, 2015, and April 5, 2017, six patients were enrolled in phase 1b (n=3 received 2 mg/kg pembrolizumab, n=3 received 10 mg/kg pembrolizumab) and 52 patients in phase 2 (n=40 had PD-L1-positive tumours, n=12 had PD-L1-negative tumours). The data cutoff for this analysis was Aug 7, 2017. During phase 1b, there were no dose-limiting toxicities in the dose cohorts tested. Median follow-up for the phase 2 cohort was 13·6 months (IQR 11·6-18·4) for patients with PD-L1-positive tumours, and 12·2 months (7·9-12·2) for patients with PD-L1-negative tumours. Six (15%, 90% CI 7-29) of 40 PD-L1-positive patients achieved an objective response. There were no objective responders among the PD-L1-negative patients. The most common treatment-related adverse event of any grade was fatigue (12 [21%] of 58 patients). Grade 3-5 adverse events occurred in 29 (50%) of patients, treatment-related grade 3-5 adverse events occurred in 17 (29%), and serious adverse events occurred in 29 (50%) patients. The most commonly occurring serious adverse events were dyspnoea (n=3 [5%]), pneumonitis (n=3 [5%]), pericardial effusion (n=2 [3%]), and upper respiratory infection (n=2 [3%]). There was one treatment-related death due to Lambert-Eaton syndrome in a PD-L1-negative patient during phase 2. INTERPRETATION: Pembrolizumab plus trastuzumab was safe and showed activity and durable clinical benefit in patients with PD-L1-positive, trastuzumab-resistant, advanced, HER2-positive breast cancer. Further studies in this breast cancer subtype should focus on a PD-L1-positive population and be done in less heavily pretreated patients. FUNDING: Merck, International Breast Cancer Study Group.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Loi S, Giobbie-Hurder A, Gombos A, et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. Lancet Oncol. 2019. PMID: 30765258. doi:10.1016/S1470-2045(18)30812-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。